Related Experiment Video
Updated: Jul 10, 2026
05:14
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
Serotonin-1A receptors in frontotemporal dementia compared with controls
Krista L Lanctôt1, Nathan Herrmann, Hooman Ganjavi
1Department of Psychiatry, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. krista.lanctot@sunnybrook.ca
Psychiatry Research
|November 3, 2007
Summary
Frontotemporal lobar dementia (FTLD) patients showed significantly reduced serotonin 5-HT(1A) binding potential in the brain compared to controls. These findings suggest serotonin deficits may impact FTLD symptoms and treatment outcomes.
Area of Science:
- Neuroscience
- Radiology
Background:
- Frontotemporal lobar dementia (FTLD) is a neurodegenerative disease affecting behavior, language, and motor functions.
- The neurochemical underpinnings of FTLD, particularly serotonergic system involvement, remain incompletely understood.
Purpose of the Study:
- To investigate serotonin 5-HT(1A) receptor binding potential in patients with frontotemporal lobar dementia (FTLD) using positron emission tomography (PET) neuroimaging.
- To explore the potential relationship between serotonin 5-HT(1A) binding and FTLD symptomatology or treatment response.
Main Methods:
- Positron emission tomography (PET) neuroimaging was employed to measure serotonin 5-HT(1A) binding potential (BP).
- Four patients diagnosed with FTLD were compared with healthy control subjects across 10 predefined brain regions.
Main Results:
- Significantly decreased serotonin 5-HT(1A) binding potential (BP) was observed in all 10 examined brain regions in FTLD patients compared to controls.
- These reductions were statistically significant, indicating a widespread impact on the serotonergic system.
Conclusions:
- Pilot data suggest profound losses in serotonin 5-HT(1A) BP are present in FTLD.
- These deficits may play a crucial role in the development of FTLD symptoms and influence patient response to therapeutic interventions.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...